Groowe Groowe / Newsroom / OVID
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

OVID News

Ovid Therapeutics Inc. Common Stock

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

globenewswire.com
OVID